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Abstract
Pro-inflammatory activation of vascular endothelium is implicated in pathogenesis of severe conditions including stroke,
infarction and sepsis. We have recently reported that superoxide dismutase (SOD) conjugated with antibodies (Ab/SOD)
that provide targeted delivery into endothelial endosomes mitigates inflammatory endothelial activation by cytokines and
agonists of Toll-like receptors (TLR). The goal of this study was to appraise potential utility and define the mechanism of this
effect. Ab/SOD, but not non-targeted SOD injected in mice alleviated endotoxin-induced leukocyte adhesion in the cerebral
vasculature and protected brain from ischemia-reperfusion injury. Transfection of endothelial cells with SOD, but not
catalase inhibited NFkB signaling and expression of Vascular Cell Adhesion Molecule-1 induced by both cytokines and TLR
agonists. These results affirmed that Ab/SOD-quenched superoxide anion produced by endothelial cells in response to
proinflammatory agents mediates NFkB activation. Furthermore, Ab/SOD potentiates anti-inflammatory effect of NO donors
in endothelial cells in vitro, as well as in the endotoxin-challenged mice. These results demonstrate the central role of
intracellular superoxide as a mediator of pro-inflammatory activation of endothelium and support the notion of utility of
targeted interception of this signaling pathway for management of acute vascular inflammation.
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Introduction
Pro-inflammatory activation of vascular endothelium caused by
ischemia, infectious agents, cytokines, reactive oxygen species
(ROS) including superoxide and H2O2 and other pathological
mediators, is implicated in cardiac, pulmonary, cerebral and
peripheral vascular pathology [1,2,3,4]. Such activation, mani-
fested among other signs by expression of cell adhesion molecules
including vascular cell adhesion molecule 1 (VCAM), in turn
aggravates inflammation via adhesion and trafficking of activated
leukocytes, enhanced vascular permeability and thrombosis [5].
Recent studies implicated ROS produced by vascular cells as both
injurious agents and pro-inflammatory signaling mediators in
vascular pathology [6]. In particular, ROS produced by NADPH
oxidase in the lumen of endothelial endosomes in response to
cytokines, are implicated in signaling for pro-inflammatory
endothelial activation [7]. Interruption of this pathological
pathway may provide a new means for alleviation of uncontrolled
vascular inflammation implicated in the pathogenesis of devastat-
ing conditions including acute lung injury (ALI), stroke and
myocardial infarction.
Results of our recent study suggest that this goal can be achieved
by targeted delivery of antioxidant enzymes to endothelial cells [8].
Conjugation with antibodies to endothelial surface marker
molecule platelet endothelial cell adhesion molecule 1 (PECAM)
provides targeted delivery of antioxidant enzymes catalase and
superoxide dismutase (SOD) into endothelial cells of lungs, heart
and brain [9,10,11]. In particular, SOD conjugated with anti-
PECAM (Ab/SOD) binds to and enters endothelial endosomes,
quenches superoxide in endosomes and inhibits cytokine-induced
pro-inflammatory VCAM expression induced by cytokines or
agonists of Toll-like receptors (TLR) [8,12]. Non-targeted SOD
formulations including polyethylene glycol (PEG)-conjugated
SOD, which have no affinity to endothelium and little, if any,
access to intracellular superoxide, do not afford this effect despite a
much higher level in the blood [8]. These findings unraveled a
new paradigm for protective effects of targeted antioxidants, an
area of active translational research that yielded encouraging pre-
clinical results in animal models of oxidative stress, ischemia and
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inflammation [13]. In the present study, we investigated the
mechanism and translational potential of the anti-inflammatory
action of Ab/SOD in vitro and in vivo.
Materials and Methods
Reagents, Antibodies and Conjugates
Cytochrome c, xanthine oxidase, xanthine (3,7-dihydro-purine-
2,6-dione), dimethylformamide (DMFA) and fetal bovine serum
were purchased from Sigma (St. Louis, MO). Cu, Zn-superoxide
dismutase (SOD) and catalase from bovine liver are from
Calbiochem (San Diego, CA). Succinimidyl-6-[biotinamido]hex-
anoate (NHS-LC-biotin), 4-[N-maleimidomethyl]cyclohexane-1-
carboxylate (SMCC), N-succinimidyl-S-acetylthioacetate (SATA)
were from Pierce Biotechnology (Rockford, IL). Anti-PECAM
monoclonal antibodies used were mAb 62, a monoclonal antibody
directed against human Platelet-Endothelial Cell Adhesion Mol-
ecule-1 (PECAM) [11,14] and MEC-13.3 (BD Biosciences, San
Jose, CA) towards murine PECAM. Anti-PECAM/SOD conju-
gates were prepared via amino-chemistry as described earlier [8].
Tumor necrosis factor (TNF) and IL-1b were from BD Biosciences
(Bedford, MA).
Cell Culture and Treatment
Human umbilical endothelial cells (HUVEC; Lonza Walkers-
ville, Walkersville, MD) were maintained in EGM-2 BulletKit
medium (Lonza) with 10% fetal bovine serum supplemented with
100 U/ml penicillin and 100 mg/ml streptomycin (GIBCO) in
Falcon tissue culture flasks (BD Biosciences, San Jose, CA) coated
with 1% gelatin. For activation cells were starved overnight in
EBM-2 with 0.5% fetal bovine serum and TNF, IL-1b or poly(I:C)
were added to cells for 4–5 h. Lipopolysaccharide (LPS) was added
to cells in complete EGM-2 medium.
Cell Transduction
HUVEC were transduced with adenoviruses Ad-CMV-Lucif-
erase, Ad-NFKb-Luciferase, Ad-SOD1 or Ad-Catalase (Vector
Biolabs, Philadelphia, PA) by exposing cells with indicated titer
(and MOI) for 2 h. HUVEC were first plated in complete
HUVEC EBM medium (10% FBS, EBM and additives; Clonetics)
and allowed to grow for 3 days until confluence culture. Then cells
were trypsinized, harvested and plated on 96 well culture dishes
for luciferase experiments (on 24 well culture dishes in case of
transfection with catalase- or SOD-containing viruses) at low
density (1:4 by square area) for 16 h. Cells were exposed to
increasing concentrations of adenoviruses for 2 h, washed and
incubated for 24 h with fresh medium. In experiments with
luciferase-containing adenoviruses cells were further pre-treated
with Ab/SOD followed by activation with TNF for another 4 h
before luciferase activity assay. Preliminary studies showed dose-
dependent increasing luciferase expression by TNF-treated cells
with the increase of Ad-NFkB-Luc dose. Optimal vector
concentration was chosen as 200 MOI (26107 PFU/ml) and used
for SOD targeting experiments. Cells were preincubated for 1 h
with Ab/SOD and treated with 10 ng/ml TNF for 4 h.
Transfection was done next day for 2 h in same medium, medium
was refreshed and cells were allowed to grow for 24 h before
experimental treatment. Ad-CMV-Luciferase was used as a
positive control in preliminary experiments. Luciferase activity
was measured using RapidReporter Gaussia Luciferase Assay
(Active Motif, Carlsbad, CA). Luciferase protein was assayed by
Western blotting.
Western Blotting
Cells in 24 well culture dishes (app. 100,000 cells per well) were
washed twice with phosphate-buffered saline (PBS) and lysed in
100 ml of sample buffer for sodium dodecyl sulfate polyacrylamide
gel electrophoresis. Cell proteins were subjected to 4–15%
gradient gel. Gels were transferred to PVDF membrane (Millipore)
and the membrane was blocked with 3% nonfat dry milk in TBS-
T (100 mM Tris (pH 7.5), 150 mM NaCl, 0.1% Tween 20) for
1 h followed by incubations with primary and secondary
antibodies in the blocking solution. The blot was detected using
ECL reagents (GE Healthcare). In experiments with antioxidant
enzyme transfection cells were activated with cytokines TNF, IL-
1b or with TLR4 agonist LPS for 4 h or with TLR3 agonist
poly(I:C) for 5 h.
RNA Extraction and Real-time Quantitative Reverse-
transcriptase PCR
Cells were grown on 24 well culture dishes. Total RNA was
extracted using RNeasy Mini Kit (Qiagen, Hilden, Germany) and
cDNA was synthesized using Transcriptor First Strand cDNA
Synthesis Kit (Roche) in accordance to manufacturer’s recom-
mendations. Levels of mRNA of human VCAM-1 and actin were
measured by quantitative real-time RT-PCR using gene-specific
primers (LightCycler, Roche) with SYBR green. Primers for actin
were from [15] and VCAM-1 from [16]. Reactions were
incubated at 95uC at 5 min before thermal cycling at 95uC for
15 s, 60uC for 5 s, and 72uC for 10 s. Samples were prepared in
triplicates and transcript expression was calculated by comparing
the number of thermal cycles that were necessary to produce
threshold amounts of product as described [17] and normalized by
b-actin.
Catalase and SOD Activities
Catalase and SOD activities were measured in lysates of control
and transfected cells. Catalase activity was assayed by H2O2
degradation. Cell lysate was added to working buffer contained of
3% H2O2 and 5 mM sodium phosphate buffer, pH 7.0. Degra-
dation of H2O2 was detected at 242 nm using UV-VIS
spectrophotometer Cary 50 Bio (Varian, Palo Alto, CA) and
calculated as DA/min/mg of protein. SOD activity was measured
using ferricytochrome assay [18]. Xanthine and xanthine oxidase
was used as a source of superoxide anion and cytochrome c as the
indicating scavenger of the radical competing with SOD. Working
solution contained of 50 mM phosphate buffer (pH 7.8), 0.1
EDTA, 50 mM xanthine, 20 mM cytochrome c (600 ml) and 10 ml
of cell lysate. Reaction was initiated by the addition of 10 ml of
0.2 U/ml xanthine oxidase and the absorbance was monitored at
550 nm using Cary 50 spectrophotometer. One unit of SOD
activity is defined as the amount of cell lysate, which inhibits the
rate of cytochrome c reduction by 50%.
NF-kB Nuclear Translocation
Cells were treated with TNF for 15 min. Cellular nuclear
fraction was isolated using NE-PERH Nuclear and Cytoplasmic
Extraction Reagents (Pierce). Activity of NF-kB in the nuclear
extract was measured by TransAM NFkB p65 DNA-binding
ELISA in accordance with manufacturer’s recommendations
(Active Motif, Carlsbad, CA).
IkBa Phosphorylation
Cells were grown in 6 well culture dishes (4 wells per condition),
treated with 10 mM proteasome inhibitor MG132 and HaltTM
Phosphatase Inhibitor Cocktail (Pierce) for 30 min, stimulated
Anti-Inflammatory Effect of SOD
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with TNF for 5 min. After TNF treatment cells were scrapped,
centrifuged and lyzed for Western blotting. IkBa phosphorylation
was detected using rabbit anti-IkBa antibodies (Santa-Cruz) for
loading control and rabbit anti-pS32,36-IkBa antibodies (Abcam)
for level of protein phosphorylation.
Intravital Microscopy of Leukocyte-endothelial
Interactions
Intravital microscopy for in vivo leukocyte adhesion was
performed on 8 week old male C57BL/6 mice (20–25 g). These
in vivo experiments were conducted in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health and
approved by the Institutional Animal Care and Use Committee at
Temple University (Permit Number: 3415). All surgery was
performed under ketamine/xylazine anesthesia, and all efforts
were made to minimize stress and discomfort. Intravital micros-
copy was performed on animals underwent craniotomy and
cranial window implantation after a recovery period of at least 4
days as described earlier [19,20]. For evaluation of leukocyte
rolling and adhesion, cells were stained in vivo by an i.p. injection
of 200 ml of a 0.05% Rhodamine 6G. The conjugates were
administered i.v. 30 min before i.p. LPS (from E. coli 0127:B8)
injection. Intravital imaging was performed 4 h post LPS
injection. Observation of surface cerebral vessels though cranial
window was performed with a Stereo Discovery V20 epifluores-
cence microscope (Carl Zeiss Microimaging Inc., Thornwood,
NY) as described [20]. A 30-s video (at 16–20 frame/s) was
captured by digital high speed recorder Axiovision module and
analyzed using the Imaris imaging software (Bitplane AG,
Switzerland).
Cerebral Reperfusion Model
Transient middle cerebral artery occlusion (MCAO) model
(30 min of ischemia followed by 48 h of reperfusion) was
performed on mice. Briefly, the left common and internal carotid
arteries were ligated and the external carotid artery was isolated
and incised. Silicon-covered nylon filament (Doccol) was intro-
duced into the external carotid artery with MCAO with
subsequent reperfusion and advanced to the middle cerebral
artery for 30 min. as described elsewhere [21,22]. All procedures
were performed in strict accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health and approved by the Massachusetts
General Hospital Subcommittee on Research and Animal Care
(Permit Number: 2003N000297). Surgery was performed under
isoflurane anesthesia, and all efforts were made to minimize
suffering. For measurements of the infarct volume brain tissue was
cut into 2-mm-thick coronal blocks, immersed in 2,3,5-triphenyl-
tetrazolium chloride for 12 h. The area of infarction in each
section was expressed as a fraction of the non-ischemic part of
ipsilateral hemisphere (indirect volume of infarct) as described
elsewhere [22].
Endotoxemia Model in Mice
This study was performed on 6–8 week old male C57BL/
6 mice (20–25 g) and was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the University of Pennsylvania (Permit Number:
803375). All surgery was performed under ketamine/xylazine
anesthesia, and all efforts were made to minimize suffering.
Conjugates or non-conjugated antioxidant enzymes (150 mg of
SOD) were injected 30 min prior LPS (from E. coli O55:B5,
200 mg/kg) via tail vein [8]. In 5 hours after LPS challenge lungs
were perfused and harvested. VCAM-1 expression level was
assayed by Western blot. Plasma TNF and MIP2 level were
measured by ELISA using Mouse TNF-a and Mouse CXCL2/
MIP-2 Quantikine kits (R&D Systems, Minneapolis, MN).
Statistical Analyses
Statistical significance was estimated by Student t-test.
Results
Protective Effects of Ab/SOD in Animal Models of
Vascular Inflammation
Our initial study documented that Ab/SOD inhibits cytokine-
induced endothelial expression of inducible adhesion molecule
VCAM in vitro and in vivo [8]. VCAM supports leukocyte adhesion
to endothelium at sites of inflammation, and, therefore, by
inhibiting this and other pro-inflammatory pathways, Ab/SOD
may suppress inflammation [5]. In order to appraise the
physiological and potential therapeutic effect of this targeted
antioxidant intervention, we tested it in models of acute vascular
inflammation.
First, in a model of endotoxin encephalitis, mice with implanted
cranial window for observation of surface cerebral vessels were
injected with LPS [19]. This caused a firm adhesion of leukocytes
to the vessel wall with just a few rolling leukocytes (Fig. 1A and B).
The images were processed for automated particle counting
(identifying the location of the leukocytes) showing also vector/
track projections to enable the distinction between rolling and
attached cells. Ab/SOD attenuated endotoxin-induced leukocyte
adhesion in the cerebral vessels: note the drastic decrease of
adherent leukocytes and increased level of rolling cells unable to
anchor to the endothelium (Fig. 1C). Therefore, quenching
endothelial superoxide by Ab/SOD does provide anti-inflamma-
tory effects in vivo consistent with the observed earlier suppression
of endothelial cell adhesion molecules [8].
Based on these encouraging results, we tested whether targeting
enzymes quenching endothelial ROS provides tangible therapeu-
tic benefits in an animal model that resembles ischemic stroke in
humans, namely, a mouse model of MCAO by filament followed
by reperfusion [21,22]. Injection of antioxidant enzymes (AOE,
catalase and SOD) or PEG-conjugated AOE that have prolonged
circulation and enhanced systemic bioavailability had no effect on
the brain infarction size (Fig. 1D). In contrast Ab/AOE
significantly attenuated cerebral injury in this model (Fig. 1D).
Ab/SOD Inhibits NF-kB Pathway Activation by Cytokines
Next we studied the mechanism of the protective effects. Our
previous work established that Ab/SOD targeted to PECAM
binds to endothelial cells, delivers SOD into endosomes and
inhibits VCAM expression induced by cytokines or TLR agonists,
whereas Ab/catalase or untargeted enzymes including PEG-SOD
did not have this effect [8]. To elucidate the mechanism of action
of Ab/SOD, we tested whether the targeted SOD can directly
affect the NF-kB signal transduction pathway, known to play the
central role in endothelial activation by cytokines [23].
For this purpose we used HUVEC transfected with luciferase
reporter Ad-NFkB-Luc driven by NF-kB response element,
showing dose dependent response to TNF (Fig. 2A). In this model
system Ab/SOD inhibited TNF-induced NF-kB activation by
40% (Fig. 2B). To confirm this outcome, we tested the effect of
Ab/SOD on NF-kB nuclear translocation. Using ELISA for the
Anti-Inflammatory Effect of SOD
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detection of p65 subunit of NF-kB we found that Ab/SOD, but
not untargeted free SOD significantly decreased the TNF-
enhanced nuclear p65 level by ,30% (not shown).
Therefore, Ab/SOD inhibits cytokine-induced NF-kB activa-
tion in endothelial cells, which can suppresses its downstream
effects. This notion was supported by the effects of Ab/SOD on
VCAM mRNA level measured by qPCR. Preliminary data on the
kinetics of VCAM mRNA expression in response to TNF showed
that in 1 h after addition of the cytokine the level of VCAM
mRNA was augmented 53-fold (Fig. 3A). Further we observed that
in 1 h after TNF exposure Ab/SOD, but not untargeted free SOD
significantly decreased the level of VCAM mRNA by 40%
(Fig. 3B). Consistent with previous study [8] protein level of
VCAM was profoundly attenuated by cell treatment with Ab/
SOD (Fig. 3B, inset). It is not clear, how this relatively fair decrease
in VCAM mRNA results in a profound suppression observed at
the protein level. A change in turnover, shedding, degradation or
misfolding of the transcribed protein, either constitutive or
aberrant due to altered redox state, seems as plausible explana-
tions.
Endothelial Activation by Diverse Pro-inflammatory
Agonists is Mediated by Intracellular Superoxide
These results square well with previous findings that Ab/SOD
inhibited VCAM synthesis induced by cytokines (TNF and IL-1b)
or TLR agonists (LPS and poly(I:C)) [8]. These agonists act upon
different cognate receptors that, upon ligand engagement, undergo
endocytosis via either caveolar (TNF, IL-1b and LPS) or clathrin-
mediated (poly(I:C)) pathways and concomitantly activate
NADPH oxidase in endosomal membrane, which fluxes ROS
into the endosomal lumen (see Discussion for details). Quenching
superoxide in endosomes attained by Ab/SOD or blocking the
anion channel ClC3 responsible for the transfer of superoxide
from endosomes to cytosol inhibited cell activation [8].
To understand whether superoxide transported from endo-
somes to cytosol acts as the direct signaling molecule or rather
serves as precursor of hydrogen peroxide acting upon cognate
cytosolic sensors, we transfected cells with SOD1 or catalase using
adenoviral vectors. This approach provided a dose-dependent
elevation of the enzymatic activity in cell lysates that reached
maximal levels of 200-fold and 6-fold increase over the basal level
for catalase and SOD, respectively (Fig. 4, A and B). Further we
demonstrated that expression of SOD, but not catalase inhibited
Figure 1. Protective effects of PECAM-directed Ab/AOE targeting in vivo. (A–C). SOD targeting inhibits leukocyte adhesion to surface
cerebral vessels in an in vivo model of inflammation. Mice were intravenously injected with PBS (A), LPS (B) or anti-PECAM/SOD and LPS (C). Labeled
leukocytes interaction with endothelium of cerebral vessels was monitored by intravital microscopy through an implanted cranial window at 4 h after
the injection. Observation of labeled leukocyte rolling was performed during a 30 s (16–20 frames/s) time-series acquisition. The spots denote the
identified leukocytes by the automated particle counting function provided the image analysis. Displacement vectors are shown as tracks to indicate
whether the cell is attached (no vector) or rolling (vectors of various lengths) during the image acquisition time interval. (D). Systemic administration
of antioxidant enzymes (AOE) SOD and catalase conjugated with PECAM antibody (Ab/AOE) alleviates brain infarction in the filament model of MCAO.
* P,0.05, n = 7 (control), 3 (free AOE), 5 (Ab/AOE), and 3 (PEG-AOE).
doi:10.1371/journal.pone.0077002.g001
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VCAM expression induced by TNF, IL-1b, LPS or poly(I:C)
(Fig. 4, C and D). Moreover, the inhibitory effects of SOD clearly
depended on its expression level (Fig. 4D).
The Combined Effect of Ab/SOD and Exogenous NO
Donors
Nitric oxide is known to inhibit NF-kB pathway in endothelial
cells [24,25]. Based on the fact that the mutual influences of NO
and ROS are of paramount importance in vascular biology,
inflammation and vessel tone control [26,27], we wanted to study
the interrelationships between Ab/SOD and NO donors in the
context of cytokine activation of endothelium.
First, we refined the dose dependence of inhibition by NO-
donor SNAP of the TNF-induced NF-kB activation and VCAM
expression in endothelial cells (Fig. S1). Therefore, we choose the
doses of Ab/SOD and SNAP (20 mg/ml and 0.2 mM, respective-
ly), which individually caused rather marginal inhibition of TNF-
induced endothelial activation. Using these rate-limiting doses we
found that combined treatment of TNF-activated cells with Ab/
SOD and SNAP lead to significant decrease of IkBa phosphor-
ylation (Fig. 5, A and B) and complete inhibition of VCAM
expression (Fig. 5, C and D). In contrast, non-targeted SOD did
not potentiate the anti-inflammatory effect of SNAP (Fig. 5, C and
D); which implies that it is interception of intracellular superoxide
poorly accessible to free SOD in the medium plays the key role in
augmentation of effects NO.
The results suggest that two potential therapeutics exerting
distinct activities (targeted SOD and systemic NO donors) can act
in concert to alleviate vascular oxidative stress and inflammation.
To test this intriguing scenario in vivo, we used mouse model of
endotoxin challenge, leading to pro-inflammatory elevation of
VCAM-1 in the pulmonary vasculature [8]. Analysis of the lung
homogenate revealed that combined treatment with Ab/SOD and
Figure 2. PECAM-directed Ab/SOD delivery to endothelium
inhibits TNF-activated NF-kB signaling. (A). Expression of NFkB-
dependent luciferase by TNF-activated cells. HUVEC were transfected
for 2 h with Ad-NFkB-Luc at 16107 PFU/ml (100 MOI), vector was
washed out and cells were incubated for 16 h followed by activation
with 10 ng/ml TNF for 4 h. Cells were lysed. Luciferase expression was
assessed by Western blotting (inset), luciferase activity was measured
by Luciferase activity assay (Promega). (B). Effects of Ab/SOD targeting.
HUVEC were transfected with Ad-NFkB-Luc at 16107 PFU/ml (100 MOI)
for 2 h, vector was washed out and cells were incubated for 16 h.
Transfected cells were treated with Ab/SOD targeted to PECAM for 1 h
and activated with 10 ng/ml TNF for 4 h. Cells were lysed and luciferase
activity was measured by Luciferase activity assay (Promega). Non-
transfected cells (without or with TNF activation) did not show
luciferase activity. Mean6SEM are shown, * P,0.05, n = 4.
doi:10.1371/journal.pone.0077002.g002
Figure 3. PECAM-directed Ab/SOD targeting to endothelial
cells inhibits TNF-induced synthesis of VCAM. (A). Kinetics of
synthesis of VCAM after endothelial cells induction by 10 ng/ml TNF as
measured by qPCR. (B). Effects of Ab/SOD targeting. Cells were
pretreated with anti-PECAM/SOD or untargeted SOD for 1 h and
activated with 10 ng/ml TNF. Level of VCAM mRNA was measured by
qPCR in 1 h. *p,0.05 vs. control. (Inset), representative Western blot
analysis of VCAM protein after 5 h.
doi:10.1371/journal.pone.0077002.g003
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NO-donor PAPA NONOate at rate-limiting doses that failed
individually provided nearly complete suppression of LPS-induced
VCAM expression in the pulmonary vasculature (Fig. 6, A and B).
Furthermore, analysis of plasma TNF and MIP-2 levels revealed
a very similar outcome: used in a concert, NO-donor and Ab/
SOD afforded significantly more potent suppression of cytokine
level in blood in response to endotoxemia (Fig. 6, C and D,
respectively). Thus, NO donor and Ab/SOD attenuated both
local (lung VCAM) and systemic (plasma cytokines) inflammatory
markers.
Discussion
Targeted delivery of antioxidant enzymes (e.g., catalase and
SOD) to endothelial cells affords multifaceted protective effects in
diverse pathological settings associated with vascular oxidative
stress [13,28]. Affinity ligands used for this purpose include
antibodies and antibody fragments binding to PECAM
[9,10,29,30], ICAM-1 [31,32] and angiotensin-converting enzyme
[33], as well as peptides binding to glycocalyx [34]. Ab/catalase is
protective against lung injury caused by ischemia-reperfusion
[33,35,36], whereas Ab/SOD attenuates angiotensin-II caused
vasoconstriction [35], as well as cytokine-induced inflammation
[8] and trans-endothelial permeability [37]. Such a functional
selectivity of Ab/catalase vs Ab/SOD, taken together with lack of
effects of non-targeted enzymes including PEG-conjugated
enzymes, imply that in order to achieve protective effects it is
necessary to quench ROS specifically in the target cells, i.e.,
endothelium. Results of the present study recapitulate this
paradigm and shed light on the mechanisms and translational
potential of targeted interception of superoxide in the endothelial
cells.
Pro-inflammatory endothelial activation by agonists involves
distinct series of receptors and endocytic pathways. Cytokine
receptors IL-1R1 [38] and TNFR1 [39,40,41] as well as TLR4
[42] act predominantly via caveolae-mediated endocytosis [43],
whereas activation of intracellular receptors such as TLR3
depends on clathrin-mediated endocytosis of dsRNA [44]. Earlier
it was demonstrated that TNF-mediated activation of NFkB
pathway may be inhibited by transient overexpression of cytosolic
Figure 4. SOD1, but not catalase overexpression in endothelial cells inhibits VCAM expression induced by cytokines or TLR
agonists. A–B. HUVEC were transfected with increasing doses (0–106107 PFU/ml; 0–1000 MOI) of either Ad-Cat or Ad-SOD1 adenoviral vectors.
Enzyme activities of catalase (A) or SOD (B) were measured in corresponding cell lysate to test the level of the antioxidant enzyme expressions. C–D.
Effects of catalase and SOD1 overexpression on cellular responsiveness to cytokines and TLR agonists were assayed by Western blotting of VCAM.
Cells transfected with increasing doses (0–56107 PFU/ml; 0–500 MOI) of Ad-Cat (C) or Ad-SOD1 (D) were activated with 10 ng/ml TNF, 10 ng/ml Il-1b,
0.5 mg/ml TLR4 agonist LPS, or 20 mg/ml TLR3 agonist poly(I:C). VCAM expression was detected in 4 h for TNF, IL-1b and LPS treatment or in 5 h for
poly(I:C) treatment.
doi:10.1371/journal.pone.0077002.g004
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SOD1 [45,46] or mitochondrial SOD2 [47,48], but not catalase
[49,50]. Stable expression of catalase also inhibited TNF-induced
NF-kB [51], due to probably more general alteration of cell
functions [49]. In the present study expression of SOD, but not
catalase in the cytosol, inhibited signal transduction from cytokine
receptors and TLRs to NF-kB path. This result implicates
superoxide transferred into the cytosol from endosomes as a
direct signaling molecule, and warrants further studies to reveal a
cytosolic target of signaling superoxide. Thus, our results help to
resolve the controversy, affirming that superoxide, but not H2O2
mediates NF-kB activation and VCAM expression caused by the
array of pro-inflammatory agents acting via distinct receptors and
endosomes (Figure 4). From the therapeutic perspective, our
results imply that targeted delivery of SOD into endothelial cells
intercepts the ROS in signaling endosomes prior to its transfer to
the cytosol, thereby providing anti-inflammatory effect.
Many processes in vascular physiology and pathology including
ischemia and inflammation involve multifaceted interactions
between ROS and nitrogen species in endothelial cells [4,52]. In
particular, superoxide rapidly reacts with nitric oxide, forming a
strong oxidant ONOO2 and abolishing effects of NO [26].
Previously we have shown that Ab/SOD normalizes vasoregula-
tion in angiotensin II-treated mice by preserving NO endoge-
nously produced by endothelial NOS [35]. Data obtained in the
present study indicate that Ab/SOD also augments anti-inflam-
matory effects of exogenous NO donors, both in cell culture and in
animal model (Fig. 5 and 6). The precise mechanism of the
potentiation is still to be elucidated. It’s not clear yet whether SOD
effect is due to NO preservation or to inhibition of the signaling in
NO-independent manner. It is tempting to postulate that
potentiation of the effect of the combination of NO donors with
targeted SOD may be used to increase efficacy and reduce
therapeutic doses of both drugs. Considering multiple systemic
effects of NO including hypotension and platelet inhibition,
protective anti-inflammatory effect of combined delivery of SOD
and NO donors can be improved, in theory, by targeted co-
delivery of both agents. The nanocarriers containing NO-donors
have been devised and tested in animal studies [53,54] and may
provide a helpful platform for this goal. Further development of
this approach, for example, co-loading SOD and NO-donors in
hydrogel nanoparticles decorated with targeting antibodies seems
warranted.
Studies in mouse models of acute inflammatory insults in
cerebral and pulmonary vasculature confirmed the hypothesis that
Ab/SOD affords superior protective effects vs untargeted SOD
formulations including long-circulating PEG-SOD (Fig. 1D and
[8]). It has been shown recently that pluronic based polymer
nanoparticles containing catalase and SOD (‘‘nanozyme’’) protect
brain against ischemia/reperfusion in a MCAO model in rats
[55]. This model, also used in our study, recapitulates many
pathological components typical of ischemic stroke in humans and
is characterized by endothelial exposure of cell adhesion molecules
and leukocyte-mediate inflammatory brain injury [22,56]. Inter-
estingly, ‘‘nanozyme’’ also provided superior outcomes vs standard
PEG-enzymes in chronic models of central nervous system
pathology including neurodegenerative conditions [57]. In con-
trast with Ab/SOD, nanozymes are not targeted to endothelium
and the mechanism of their effect can be rather attributed to
enhanced permeation into the central nervous system parenchy-
ma, where they may protect neurons [58]. It is tempting to
postulate that a combination of targeted delivery of antioxidant
enzymes into endothelium and accumulation in the CNS
parenchyma attained by Ab/conjugates and nanozymes, respec-
tively, may afford the most effective protection. This scenario is
worth experimental testing including side-by-side characterization
of the pharmacokinetics and tissue uptake of these prospective
therapeutic agents. In any case, mechanisms of their effects need to
Figure 5. Ab/SOD potentiates anti-inflammatory effect of NO
donor SNAP in vitro. (A–B). Western blotting analysis of IkBa
phosphorylation. HUVEC were treated with SNAP (0.2 mM), washed,
treated with anti-PECAM/SOD (20 mg/ml SOD) for 1 h followed by
activation with TNF (10 ng/ml) for 10 min. Western blotting (A) and
level of phosphorylated IkBa normalized by total IkBa (B) are shown.
(C–D). VCAM expression by HUVEC co-treated with SNAP and anti-
PECAM/SOD. Experimental conditions described above. Cells were
activated with TNF for 4 h. Western blotting (C) and VCAM level
normalized by actin (D) are shown. Representative images from at least
three experiments are shown.
doi:10.1371/journal.pone.0077002.g005
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be further defined in order to support their medical and
investigational use.
In conclusion, results presented in this paper affirm the central
role of superoxide transferred from endosomes to cytosol in pro-
inflammatory activation of endothelium by cytokines and TLR
ligands. Our data also indicate that interception of this signal by
targeted delivery of Ab/SOD may provide both direct anti-
inflammatory effect(s) and augment those of other anti-inflamma-
tory agents such as NO donors. This warrants further elucidation
of mechanisms, pharmacokinetics, translational potential and
challenges of targeted antioxidants, solo and in combination with
other means including NO donors and nanozymes.
Supporting Information
Figure S1 Inhibition of TNF-induced NF-kB signal transduction
by NO donor SNAP. (A). Inhibition of NFkB-dependent luciferase
activity in TNF-activated transfected cells by SNAP. HUVEC
were transfected for 2 h with Ad-NFkB-Luc at 100 MOI
(16107 PFU/ml), vector was washed out and cells were incubated
for 16 h. After that cells were treated with indicated concentration
of SNAP for 30 min, washed and exposed to 10 ng/ml TNF for
4 h. Luciferase activity was measured by Luciferase activity assay
(Promega). (B–C). Inhibition of VCAM-1 expression. Cells were
pre-treated with SNAP for 30 min, washed and activated with
TNF (10 ng/ml) for 4 h. VCAM-1 expression was assayed by
Western blotting (B) and normalized by actin (C).
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